Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G L Wampler

Showing results (11-20 of 53) with videos related to

Pageof 6
Sort By:
Oncology|January 1, 1982
Effect of a delta 5-homo-aza-steroidal ester in P388 and L1210 murine leukemiasP Catsoulacos, C Camoutsis, G L Wampler
Cancer Chemotherapy and Pharmacology|January 1, 1979
Clinical study of hydrazine sulfate in advanced cancer patientsE Spremulli, G L Wampler, W Regelson
International Journal of Radiation Oncology, Biology, Physics|May 1, 1983
The radioenhancement effects of 5-thio-D-glucose and insulin in vivo on a hypoxic P388 murine leukemiaR Belgrad, G L Wampler, T Hazra
Cancer Chemotherapy Reports|April 1, 1973
Phase I study of tilorone, a non-marrow depressing antitumor agentG L Wampler, M Kuperminc, W Regelson
Cancer Chemotherapy and Pharmacology|January 1, 1983
Antitumor activity of homo-aza-steroidal esters of [p-[bis(2-chloroethyl)amino]phenyl]acetic acid and [p-[bis(2-chloroethyl)amino]phenyl]butyric acidP Catsoulacos, D Politis, G L Wampler
Cancer Chemotherapy and Pharmacology|January 1, 1979
A new steroidal alkylating agent with improved activity in advanced murine leukemiasP Catsoulacos, D Politis, G L Wampler
International Journal of Radiation Oncology, Biology, Physics|September 1, 1979
Radiation potentiating effect of ethyl bis(2,2-dimethyl-1-aziridinyl) phosphinate (AB-163)G L Wampler, J A Wassum, R Belgrad
Cancer Treatment Reports|September 1, 1978
Interstitial pulmonary fibrosis as a complication of prolonged methyl-CCNU therapyW Lee, R P Moore, G L Wampler
European Journal of Cancer|September 1, 1978
Absence of cross-resistance to alkylating agents in cyclophosphamide-resistant L1210 leukemiaG L Wampler, W Regelson, T J Bardos
Biometrics|September 1, 1980
Survival analysis of drug combinations using a hazards model with time-dependent covariatesD M Stablein, W H Carter, G L Wampler
Pageof 6

Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
Oncology|January 1, 1982
Effect of a delta 5-homo-aza-steroidal ester in P388 and L1210 murine leukemiasP Catsoulacos, C Camoutsis, G L Wampler
Cancer Chemotherapy and Pharmacology|January 1, 1979
Clinical study of hydrazine sulfate in advanced cancer patientsE Spremulli, G L Wampler, W Regelson
International Journal of Radiation Oncology, Biology, Physics|May 1, 1983
The radioenhancement effects of 5-thio-D-glucose and insulin in vivo on a hypoxic P388 murine leukemiaR Belgrad, G L Wampler, T Hazra
Cancer Chemotherapy Reports|April 1, 1973
Phase I study of tilorone, a non-marrow depressing antitumor agentG L Wampler, M Kuperminc, W Regelson
Cancer Chemotherapy and Pharmacology|January 1, 1983
Antitumor activity of homo-aza-steroidal esters of [p-[bis(2-chloroethyl)amino]phenyl]acetic acid and [p-[bis(2-chloroethyl)amino]phenyl]butyric acidP Catsoulacos, D Politis, G L Wampler
Cancer Chemotherapy and Pharmacology|January 1, 1979
A new steroidal alkylating agent with improved activity in advanced murine leukemiasP Catsoulacos, D Politis, G L Wampler
International Journal of Radiation Oncology, Biology, Physics|September 1, 1979
Radiation potentiating effect of ethyl bis(2,2-dimethyl-1-aziridinyl) phosphinate (AB-163)G L Wampler, J A Wassum, R Belgrad
Cancer Treatment Reports|September 1, 1978
Interstitial pulmonary fibrosis as a complication of prolonged methyl-CCNU therapyW Lee, R P Moore, G L Wampler
European Journal of Cancer|September 1, 1978
Absence of cross-resistance to alkylating agents in cyclophosphamide-resistant L1210 leukemiaG L Wampler, W Regelson, T J Bardos
Biometrics|September 1, 1980
Survival analysis of drug combinations using a hazards model with time-dependent covariatesD M Stablein, W H Carter, G L Wampler
Pageof 6